feed,title,long_url,short_url
Benzinga,BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates,https://benzinga.com/general/biotech/22/02/25811260/biocrysts-orladeyo-shows-long-term-benefit-with-sustained-reductions-in-attack-rates,https://bit.ly/36I548t
Benzinga,"Novocure Q4 Earnings Miss Street View, New Data Shows TTFields Initiates Downstream Anti-Tumor Response",https://benzinga.com/general/biotech/22/02/25813661/novocure-q4-earnings-miss-street-view-new-data-shows-ttfields-initiates-downstream-anti-tumor-res,https://bit.ly/3t8yBiO
